In Vivo Opportunity Kelonia's in vivo gene delivery platform enables direct reprogramming of T cells inside patients for CAR-T therapies. With KLN-1010 advancing toward an IND for relapsed and refractory multiple myeloma, there are near-term opportunities for licensing or co-development with pharma partners to expand into solid tumors and hematologic cancers.

Pipeline Breadth In addition to KLN-1010, Kelonia is developing a preclinical bispecific CAR-T targeting BCMA and CD19 and an additional undisclosed mechanism asset, offering multiple collaboration avenues across indications and stages of development.

Strategic Value Signals Industry signals and press coverage about large-scale deals in the in vivo CAR-T space, including reported interest from major pharma for Kelonia’s platform, underscore the strategic value of partnering or potential acquisition to accelerate adoption.

Funding Readiness With a Series A of 50 million dollars in 2022 and current revenue in the 25-50 million range, Kelonia has financial momentum to support early BD engagements with milestone-based payments, upfronts, and potential co-development funding.

Regional Position Based in Boston, Kelonia benefits from a robust biotech ecosystem, access to top talent, regulatory expertise, and potential collaborations with CROs and academic centers to accelerate clinical development and manufacturing partnerships.